SONIC HEALTHCARE LIMITED (SHL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

SHL

SHL - SONIC HEALTHCARE LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 3.24
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

Sonic Healthcare is one of the world's largest medical diagnostics companies, providing laboratory and imaging services to medical practitioners, hospitals, community health services, and their collective patients. It was first listed in 1987.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$19.84

18 Jun
2026

-0.040

OPEN

$19.79

-0.20%

HIGH

$19.89

1,569,954

LOW

$19.67

TARGET
$23.941 20.7% upside
Franking for last dividend paid out: 60%
OTHER COMPANIES IN THE SAME SECTOR
ACL . ALC . BMT . DOC . EBO . HLS . IDX . M7T . MPL . MVF . NHF . RHC .
FNARENA'S MARKET CONSENSUS FORECASTS
SHL: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 107.0 123.6 xxx
DPS (cps) xxx 107.0 105.4 xxx
EPS Growth xxx - 0.4% 15.6% xxx
DPS Growth xxx 0.9% - 1.5% xxx
PE Ratio xxx N/A 16.2 xxx
Dividend Yield xxx N/A 5.3% xxx
Div Pay Ratio(%) xxx 100.0% 85.3% xxx

Dividend yield today if purchased 3 years ago: 3.01%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 5.34

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 03/09 - ex-div 63.00c (franking 35%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx107.0
DPS All xxxxxxxxxxxxxxx107.0
Sales/Revenue xxxxxxxxxxxxxxx9,489.5 M
Book Value Per Share xxxxxxxxxxxxxxx1,733.3
Net Operating Cash Flow xxxxxxxxxxxxxxx1,296.8 M
Net Profit Margin xxxxxxxxxxxxxxx5.41 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx6.32 %
Return on Invested Capital xxxxxxxxxxxxxxx4.14 %
Return on Assets xxxxxxxxxxxxxxx3.21 %
Return on Equity xxxxxxxxxxxxxxx6.32 %
Return on Total Capital xxxxxxxxxxxxxxx5.95 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx446.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx461 M
Long Term Debt xxxxxxxxxxxxxxx4,710 M
Total Debt xxxxxxxxxxxxxxx5,171 M
Goodwill - Gross xxxxxxxxxxxxxxx9,315 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx674 M
Price To Book Value xxxxxxxxxxxxxxx1.55

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx462.7 M
Capex % of Sales xxxxxxxxxxxxxxx4.88 %
Cost of Goods Sold xxxxxxxxxxxxxxx7,072 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx1,637 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx231 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.3

No. Of Recommendations

7
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Ord Minnett

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

06/05/2026

5

Downgrade to Underweight from Equal-weight

$20.30

2.32%

Morgan Stanley assesses oil-linked risks in the Australian Healthcare sector, identifying Ramsay Health Care and Sonic Healthcare as the most exposed to cost inflation driven by higher oil prices.

Oil now presents a cost headwind for the sector, increasing component, consumables and freight expenses.

Lower margins and limited pricing power amplify earnings sensitivity for Ramsay and Sonic, the analysts explain. ResMed and Fisher & Paykel Healthcare are viewed as best positioned, supported by higher margins and stronger pricing power.

The broker lowers its target price for Sonic Healthcare to $20.30 from $24.20 and downgrades to Underweight from Equal-weight, citing risks around German reimbursement changes. In-Line industry view.

FORECAST
Morgan Stanley forecasts a full year FY26 EPS of 119.90 cents.
Morgan Stanley forecasts a full year FY27 EPS of 127.60 cents.

Citi

xx/xx/xxxx

3

xxxxxxx xx xxxxxxx xxxx xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

1

xxxxxxx xx xxxxxxxxxx xxxx xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

15/06/2026

3

Neutral

$22.30

12.40%

Jarden maintains a Neutral rating for Sonic Healthcare with its target price increased to $22.30 following the completion of a strategic sale and leaseback transaction for the Bowen Hills Laboratory.

The asset divestment generated immediate cash proceeds of $445m under a 20-year triple-net lease arrangement to substantially improve short-term cash flow optimisation paths.

Capital management parameters track the utilisation of unbooked accumulated capital losses to reduce transaction tax liabilities while systematically lowering overall gearing ratios.

The analyst notes near-term diluted earnings per share face minor negative adjustments to account for incremental depreciation expansions and higher embedded lease interest expenses.

The investment thesis balances these capital management benefits against ongoing global funding pressures and regulatory reimbursement headwinds across prominent European and domestic pathologies.

FORECAST
Jarden forecasts a full year FY26 dividend of 108.00 cents and EPS of 128.60 cents.
Jarden forecasts a full year FY27 dividend of 110.00 cents and EPS of 119.50 cents.
Access Extra Coverage Research History >

SHL STOCK CHART

FNArena News on SHL

Latest Healthcare services News

1
Healius Offers Digital Carrot, Base Remains Soft

May 25 2022 - Australia
2
Ramsay Stakes Future on Mental Health

Dec 20 2021 - Australia
3
Ramsay Health Care: Finally A Break-Out

Nov 09 2021 - Technicals
4
Funding Overhang Weighs On Ramsay’s Rebound

Jun 10 2021 - Australia
5
Treasure Chest: More Pfizer Growth For Ebos Group

May 24 2021 - Treasure Chest
6
Treasure Chest: Demand Pumps Ramsay Health

Mar 03 2021 - Treasure Chest
7
Healius Enjoying Testing Times

Dec 11 2020 - Australia
8
The First Connection

Dec 10 2020 - Weekly Reports
9
Subdued Recovery For Ramsay Health Care

Nov 16 2020 - Australia
10
Recovery Underway For Sonic Healthcare

Jun 25 2020 - Australia